The Effect of Beta Glucan on Cisplatin Ototoxicity

被引：10
作者：
Bayindir T. [1 ]
Iraz M. [2 ]
Kelles M. [3 ]
Kaya S. [1 ]
Tan M. [1 ]
Filiz A. [1 ]
Toplu Y. [1 ]
Kalcioglu M.T. [4 ]
机构：
[1] Department of Otorhinolaryngology, Inonu University, Malatya
[2] Department of Pharmacology, Istanbul Medeniyet University, Istanbul
[3] Department of Otorhinolaryngology, Sutcu Imam University, Kahramanmaras
[4] Department of Otorhinolaryngology, Istanbul Medeniyet University, Goztepe Hospital, Istanbul
来源：
Indian Journal of Otolaryngology and Head & Neck Surgery | 2014年 / 66卷 / 2期
关键词：
Betaglucan; Cisplatin; Otoacoustic emissions; Ototoxicity;
D O I：
10.1007/s12070-013-0623-0
中图分类号：
学科分类号：
摘要：
This study was undertaken to investigate the effect of betaglucan in ameliorating cisplatin ototoxicity. Rats were divided into four groups: cisplatin (C), cisplatin plus beta glucan (CB), beta glucan (B), and control (K). Distortion product otoacoustic emissions were elicited in 0th, 1st, and 5th days. For the group C differences were observed at 8,003 and 9,515 Hz between 0th and 5th days' measurements. In the group CB there were differences at frequencies of 3,996, 4,757, 5,660, and 6,726 Hz between 0th and 5th days' measurements. For the group B there were significant recovery in some frequencies. The observation of significant deterioration in terms of hearing in the group treated with cisplatin plus betaglucan may be suggested that depended on the increase of permeability and tissue conductance into the inner ear which may be caused by betaglucan. Further long-term follow-up studies by using different doses may clarify this matter. © 2013 Association of Otolaryngologists of India.
引用
收藏
页码：131 / 134
页数：3
相关论文
共 19 条
  • [1] Tsang R.Y., Al-Fayea T., Au H.J., Cisplatin overdose: toxicities and management, Drug Saf, 32, pp. 1109-1122, (2009)
  • [2] Blakley B.W., Gupta A.K., Myers S.F., Schwan S., Risk factor for ototoxicity due to cisplatin, Arch Otolaryngol Head Neck Surg, 120, pp. 541-546, (1994)
  • [3] de Jongh F.E., van Veen R.N., Veltman S.J., de Wit R., van der Burg M.E., van den Bent M.J., Et al., Weekly high-dose cisplatin in a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients, Br J Cancer, 88, pp. 1199-1206, (2003)
  • [4] Cleary J.A., Kelly G.E., Husband A.J., The effect of molecular weight and β-1,6-linkages on priming of macrophage function in mice by (1,3)- β-D-glucan, Immunol Cell Biol, 77, pp. 395-403, (1999)
  • [5] Jordan J., Schwade N.D., Truelson J.M., Fosfomycin does not inhibit the tumoricial efficacy of cisplatinum, Laryngoscope, 109, pp. 1259-1262, (1999)
  • [6] L-N-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity, Laryngoscope, 111, pp. 1147-1155, (2001)
  • [7] Reddel R.R., Kefford R.F., Grant J.M., Coates A.S., Fox R.M., Tattersall M.H., Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration, Cancer Treat Rep, 66, pp. 19-23, (1982)
  • [8] Tampakopoulou D.A., Sie K.C., Cisplatin ototoxicity in developing gerbils, Hear Res, 132, pp. 51-59, (1999)
  • [9] Fausti S.A., Frey R.H., Henry J.A., Olson D.J., Schaffer H.I., High-frequency testing techniques and instrumentation for early detection of ototoxicity, J Rehabil Res Dev, 30, pp. 333-341, (1993)
  • [10] Ravi R., Somani S.M., Rybak L.P., Mechanism of cisplatin ototoxicity: antioxidant system, Pharmacol Toxicol, 76, pp. 386-394, (1995)
12